Answers are grounded in this paper and cite their sources.
The liver constitutes a distinct immunological niche in which CD8+ T cells balance immune protection and tissue integrity. How chronic liver disease (CLD) remodels human liver–resident CD8+ T cells remains poorly understood. We demonstrate that activated hepatic stellate cells (HSCs) create immunoinstructive fibrotic niches that regulate liver-resident CD8+ T cell differentiation, localization, and function. CD103-expressing liver-resident CD8+ T cells accumulate with increasing fibrosis severity and preferentially localize within collagen-rich scar tissue. HSC-derived and matrix-retained TGFβ promote acquisition of a residency program characterized by upregulation of CD103, ECM-binding integrins, and adhesion molecules. Despite their increased abundance, liver-resident CD8+ T cells in CLD exhibit impaired antigen-dependent effector function, increased inhibitory receptor expression, and a transcriptional program associated with T cell dysfunction. Importantly, responses to PMA/ionomycin remain intact, indicating preserved effector competence. Mechanistically, HSCs directly suppress antigen-specific liver-resident CD8+ T cell function, with partial restoration following PD-L1/PD-L2 blockade. These findings identify the fibrotic niche as a central regulator of liver-resident CD8+ T cells and reveal how fibrosis can limit local immunosurveillance.
No takes yet. Share an insight, caveat, or question.
Finney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: